Updated:
Alphatec Holdings
Pat Miles turned Alphatec from a commoditized spine implant company into a vertically integrated MedTech competitor with over $585 million in 2024 revenue.
Alphatec Holdings
Alphatec was founded in 2005 and went public on Nasdaq in 2006, originally competing in the commoditized lower tiers of the spinal implant market. The arrival of Pat Miles as CEO in 2017 marked a fundamental reset. Miles, a former NuVasive executive, scrapped the distribution model for a captive sales force and rebuilt the product portfolio around lateral surgery and enabling technology. Today the company deploys the bulk of its operating cash flow into R&D and serial acquisitions of underperforming spine assets. The product portfolio covers lateral interbody fusion, posterior fixation, cervical solutions, and intraoperative neuromonitoring through the SafeOp subsidiary. The acquisition of EOS imaging in 2021 added full-body, low-dose imaging hardware to the capital-equipment sales channel. Key brands include the IdentiTi porous titanium interbody line and the Valence modular pedicle screw system. The geographic footprint is concentrated in the United States, with a growing direct-to-surgeon presence in Japan. Alphatec generated approximately $585 million in total revenue in fiscal 2024 (per SEC filings, February 2025), up from $92 million the year Miles arrived. The workforce has scaled to over 800 employees, predominantly in field sales and the Carlsbad engineering center. The company sustains an active M&A calendar: September 2023 brought the acquisition of three neuromonitoring companies to deepen the SafeOp integrated services model (per SEC filings, September 2023). Alphatec is a publicly traded medical device company, not a family office or allocator. The structural distinction is its vertical integration as a manufacturer, distributor, and monitoring-service provider, which means a surgeon can source implants, capital equipment, and intraoperative data from a single vendor relationship. That architecture directly challenges the traditional spine-industry separation between implant OEMs and third-party distributors.
General information
Firm type
Parent Company
Year founded
2005
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Carlsbad
Corporate office
Carlsbad, CA, United States
Principals
Patrick Miles
Chairman and Chief Executive Officer
Todd Koning
Chief Financial Officer
Sector focus
Frequently asked questions
How does Alphatec's vertical integration strategy differ from legacy spine competitors?
Alphatec owns its sales force, implant manufacturing, imaging hardware, and intraoperative neuromonitoring services directly. Competitors like Medtronic and Stryker historically rely on independent distributors and separate monitoring contracts. This structural model lets Alphatec capture more margin per surgical case while offering the surgeon a single point of procurement for implants, capital equipment, and procedural support.
How has Alphatec funded its product turnaround since 2017?
The board concentrated capital allocation authority under Pat Miles and raised equity through public offerings and convertible debt. The cash raised funded the acquisitions of SafeOp, EOS imaging, and a sequence of smaller neuromonitoring and implant companies that filled gaps in the lateral surgery portfolio. Per SEC filings, the company has operated at a net loss for most of the post-2017 period, prioritizing revenue growth and market-share capture over near-term profitability.
What is the commercial significance of the EOS imaging acquisition?
The July 2021 acquisition of EOS imaging gave Alphatec a low-dose, full-body radiology system that generates three-dimensional skeletal models useful for pre-surgical planning. Having the imaging platform in-house means Alphatec's sales representatives can place capital equipment into a hospital, which opens recurring revenue for the imaging service contracts and creates a direct purchasing channel for implants used in the procedures the EOS system helps to plan.
Is Alphatec profitable?
Alphatec has reported operating losses in recent fiscal years, including fiscal 2024, as it invests heavily in sales-force expansion, R&D, and acquisition integration. Management has publicly guided that the company is building toward sustained positive free cash flow through operating leverage on the existing commercial infrastructure, but profitability has not yet been demonstrated on an annual basis.
What is Alphatec's competitive position in the lateral spine surgery segment?
The lateral interbody fusion market is a focus area where Alphatec competes against NuVasive and other established spine companies. The company's IdentiTi porous titanium interbody implants and the Alpha Informatix neuromonitoring platform differentiate its offering by combining implant technology with real-time surgical data. The sales-force structure, heavily weighted toward lateral-surgery specialists, is designed to win cases from surgeons who previously used legacy competitor systems.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: